Cash pulled forward: buyers are funding the company's next stage in advance, and the money keeps arriving
The model's full reasoning — Q2 2022 call → NOWe need to determine if the company is receiving money or binding financial commitments ahead of the work it will pay for, and if management describes this as growing and financing/de-risking the next stage. The transcript is about Two Harbors Investment Corp., a mortgage REIT. They discuss their portfolio, MSR, and an acquisition of RoundPoint. The question is about advance funding from counterparties. Key points: They are a mortgage REIT. They buy RMBS and MSR. They have a portfolio. They mention "TBA dollar roll income" and "TBA" (To-Be-Announced) securities. In TBA, they have positions. But the question is about money arriving ahead of work. For a mortgage REIT, they might receive prepayments on mortgages? But that's not advance funding for their own work. They might have "servicing" where they collect payments? But that's not advance. They mention "MSR" (Mortgage Servicing Rights). They acquire MSR. They have a subservicing model. They are acquiring RoundPoint to bring servicing in-house. They talk about "incremental annual pre-tax earnings of approximately $20 million" from the acquisition. But that's not advance funding. They talk about "TBA dollar roll income" - that's a financing mechanism, but not advance payment from customers. They talk about "prepayment speeds" - that's about mortgages paying off early, not advance funding. The question is about "money or binding financial commitment arriving at the company ahead of the work it will pay for" - i.e., customers paying in advance. For a mortgage REIT, who are the customers? They invest in mortgages. They might have "servicing" where they collect mortgage payments, but that's not advance. They might have "flow" and "bulk" purchases of MSR. They sell MSR? They mention "we entered into agreements to sell roughly $21 billion UPB in the third quarter" - that's selling MSR, not advance funding. They also mention "TBA" - To-Be-Announced securities. In TBA, they have a position. But that's not advance funding. The essence: counterparties paying in advance for future delivery. For a mortgage REIT, they might have "servicing" where they receive fees for servicing loans, but that's earned over time. Not advance. They might have "prepayment" - but that's not advance. They might have "commitments" - but they are buying, not selling. The question is about the company receiving money ahead of work.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
SYM · Q3 2022 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes a "very significant cost float" from "strong deferred revenue on the balance sheet" that helps fund the company's growth strategy, along with improved payable terms. This ties directly to the $11.3 billion backlog and the ability to invest aggressively in scaling deployments, inventory, and operations ahead of full revenue recognition.
IONS · Q1 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and they treat this as growing and financing...YES Management describes exactly this pattern: Novartis delivered $175 million (including $75 million upfront plus $100 million equity at a premium) before the Phase IIb studies are conducted, and Bayer paid $75 million to advance IONIS-FXIRx and IONIS-FXI-LRx before full development work is complete 65-plus percent of which was already recognized in Q1.
LIND · Q2 2017 → YESThe question is about whether management describes that money or binding financial commitment is arriving at the company ahead of the work it will pay for, and if they treat this as growing and financ...YES The transcript shows management describing a clear pattern of advance bookings and forward reservations that are growing (nearly 40% year-to-date, up nearly 50% in July, highest booking day ever) and that directly de-risk and finance the next stage of growth.